We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

39 hedge funds and large institutions have $9.28M invested in GT Biopharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,800% more call options, than puts

Call options by funds: $78K | Put options by funds: $2K

4.55% less ownership

Funds ownership: 14.74% → 10.19% (-4.6%)

26% less funds holding

Funds holding: 53 → 39 (-14)

38% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 16

70% less capital inflows, than outflows

Capital inflows: $1.48M | Capital outflows: $5M

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
39
Holders Change
-14
Holders Change %
-26.42%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
16
Closed
15
Calls
$78K
Puts
$2K
Net Calls
+$76K
Net Calls Change
+$55K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$618K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$350K
3
E
Ergoteles
New York
+$205K
4
Atria Wealth Solutions
Atria Wealth Solutions
New York
+$150K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$64.4K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.96M
2
State Street
State Street
Massachusetts
-$980K
3
Morgan Stanley
Morgan Stanley
New York
-$335K
4
Northern Trust
Northern Trust
Illinois
-$315K
5
Renaissance Technologies
Renaissance Technologies
New York
-$307K

GTBP Hedge Fund Activity: Q2 2022 in Review

39 of the 5,964 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2022, worth a combined $9.28M — down 28% from $12.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of GTBP and 3 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 10 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $618K. The largest seller was BlackRock, cutting an estimated $1.96M.

  • 39 institutional investors held GT Biopharma (GTBP) as of Q2 2022, down from 53 in Q1 2022.
  • Funds reported $9.28M of GT Biopharma stock for Q2 2022, down 28% quarter-over-quarter.
  • 3 funds opened new GT Biopharma positions in Q2 2022 and 15 closed out, a net change of -12 holders.
  • The largest GT Biopharma buyer in Q2 2022 was Millennium Management, an estimated $618K added.
  • The largest GT Biopharma seller in Q2 2022 was BlackRock, an estimated $1.96M sold.

Based on aggregated 13F filings for Q2 2022.